Quantcast

Latest hypoglycemia Stories

2014-04-24 16:28:58

ORMD-0801 Oral Insulin Appeared Safe and Well-tolerated. No Hypoglycemic Events or Treatment Related Adverse Events Observed JERUSALEM, April 24, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today detailed results from its previously completed Phase IIa trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2...

2014-04-14 12:32:44

Conference Call and Webcast at 8:30 a.m. Eastern Time THE WOODLANDS, Texas, April 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2...

2014-04-11 23:24:03

Wisconsin's premiere weight loss and wellness clinic gains momentum in the fight against the obesity epidemic. Oconomowoc, WI (PRWEB) April 11, 2014 Solstice is proud to be the first independent physician clinic in the state of Wisconsin to provide this state of the art medically supervised weight loss program. Ideal Protein is a 4-Phase eating modification plan and treatment developed to stabilize the pancreas and blood sugar levels while burning fat and maintaining muscle mass and...

2014-04-08 15:47:41

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes. The treatment is the use of the peptide GLP-1 (glucagon-like peptide 1) in combination with insulin, which is now used throughout the world as a standard therapy for patients with type 2 diabetes. A team of researchers at...

2014-03-31 08:29:38

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex(® )recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin...

2014-03-26 11:16:16

A mathematical model created by Penn State researchers can predict with more than 90 percent accuracy the blood glucose levels of individuals with type 1 diabetes up to 30 minutes in advance of imminent changes in their levels -- plenty of time to take preventative action. "Many people with type 1 diabetes use continuous glucose monitors, which examine the fluid underneath the skin," said Peter Molenaar, Distinguished Professor of Human Development and Family Studies and of psychology....

2014-03-21 08:24:51

Company Introduces Next-Generation OptiScanner 6000; Platform to Add Real-Time Monitoring of Key Hemodynamic Measures in ICU Settings BRUSSELS, March 21, 2014 /PRNewswire/ -- OptiScan Biomedical Corporation, a developer of innovative continuous monitoring systems for use in intensive care units (ICU)/critical care units (CCU), introduced its next-generation OptiScanner((TM) )product as part of a special symposium at the 34(th) International Symposium on Intensive Care and Emergency Medicine...

2014-03-13 17:11:30

A rare and potentially lethal disease of newborn babies whose bodies make too much insulin may be treatable with fish oils, according to researchers from The University of Manchester. The disease, called congenital hyperinsulinism, means that the infant's brain is starved of blood sugar which can lead to brain damage or long-term disability. But by giving the children purified fish oils similar to those used to treat some heart attack patients, alongside standard medical treatment, their...

2014-03-06 08:30:51

PHILADELPHIA, March 6, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony(®) CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34(th) International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium. The study will be presented by the...

2014-03-05 08:28:11

ALBANY, New York, March 5, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Continuous Glucose Monitoring Market (Guardian Real Time, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo CGM Systems and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global continuous glucose monitoring market was valued at USD 0.37 billion in 2012 and is expected...


Latest hypoglycemia Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »
Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related